JAN 31, 2013
Santen will join other investors to fund an additional $7.9 million to develop Clearside's prospective treatments for choroidal neovascularization and inflammatory diseases of the posterior segment.
Clearside's proprietary microinjection platform delivers therapeutics to the retina and choroid via the suprachoroidal space. The FDA has approved clinical testing of a suprachoroidal injectable suspension of triamcinolone acetonide for sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions. Testing is scheduled to begin early this year.
"I cannot imagine a better alliance as we continue to understand the role the suprachoroidal space will play in dosing medicine directly to the site of retinal disease in patients experiencing retinal blindness" said Daniel White, president and CEO of Clearside Biomedical. "The collaboration with Santen prepares an avenue to develop state-of-the art medications for the critical treatment of sight-threatening disease."